

# Changes in aromatase (CYP19) gene promoter usage in non-small cell lung cancer

メタデータ	言語: eng 出版者: 公開日: 2017-10-03 キーワード (Ja): キーワード (En): 作成者: メールアドレス: 所属:
URL	<a href="http://hdl.handle.net/2297/27075">http://hdl.handle.net/2297/27075</a>

## **Changes in Aromatase (CYP19) Gene Promoter Usage in Non-Small Cell Lung Cancer**

Masashi Demura MD<sup>1,2</sup>, Yoshiki Demura MD<sup>3</sup>, Shingo Ameshima MD<sup>4</sup>, Takeshi Ishizaki MD<sup>4</sup>,  
Masato Sasaki MD<sup>5</sup>, Isamu Miyamori MD<sup>4</sup>, Masakazu Yamagishi MD<sup>6</sup>, Yoshiyu Takeda MD<sup>2</sup>,  
and Serdar E. Bulun MD<sup>1</sup>

<sup>1</sup> Division of Reproductive Biology Research, Department of Obstetrics and Gynecology,  
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA

<sup>2</sup> Division of Endocrinology and Hypertension, Department of Internal Medicine,  
Kanazawa University Graduate School of Medical Science, Kanazawa, 920-8641, Japan

<sup>3</sup> Division of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, 920-8530,  
Japan

<sup>4</sup> Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui  
Hospital, Fukui Prefecture 910-1193, Japan

<sup>5</sup> Department of Thoracic Surgery, Faculty of Medical Sciences, University of Fukui Hospital,  
Fukui Prefecture 910-1193, Japan

<sup>6</sup> Division of Cardiology, Department of Internal Medicine,  
Kanazawa University Graduate School of Medical Science, Kanazawa, 920-8641, Japan

### **Corresponding author:**

Masashi Demura, MD

Division of Endocrinology and Hypertension

Department of Internal Medicine

Kanazawa University Graduate School of Medical Science

13-1 Takara-machi, Kanazawa 920-8641, Japan

Phone: +81-76-265-2252

Fax: +81-76-234-4251

E-mail: [m-demura@med.kanazawa-u.ac.jp](mailto:m-demura@med.kanazawa-u.ac.jp)

**To whom reprint requests should be addressed:**

Serdar E. Bulun, MD

Division of Reproductive Biology Research, Department of Ob/Gyn

Feinberg School of Medicine at Northwestern University

303 E. Superior St

Robert H. Lurie Biomedical Research Building, Rm 4-123

Chicago, IL 60611, USA

Phone: 312-503-0520

Fax: 312-503-0095

E-mail: [s-bulun@northwestern.edu](mailto:s-bulun@northwestern.edu)

**Summary:** CYP19 promoter usage in lung cancer

**Key words:** non-small cell lung cancer, estrogen, aromatase, CYP19, promoter, promoter usage.

## **Abstract**

In humans, aromatase (CYP19) gene expression is regulated via alternative promoters. Activation of each promoter gives rise to a CYP19 mRNA species with a unique 5'-untranslated region. Inhibition of aromatase has been reported to downregulate lung tumor growth. The genetic basis for CYP19 gene expression and aromatase activity in lung cancer remains poorly understood. We analyzed tissues from 15 patients with non-small cell lung cancer (NSCLC) to evaluate CYP19 promoter usage and promoter-specific aromatase mRNA levels in NSCLC tumor tissues and adjacent non-malignant tissues. CYP19 promoter usage was determined by multiplex RT-PCR and aromatase mRNA levels were measured with real-time RT-PCR. In non-malignant tissues, aromatase mRNA was primarily derived from activation of CYP19 promoter I.4. Although promoter I.4 usage was also dominant in tumor tissues, I.4 activation was significantly lower compared with adjacent non-malignant tissues. Activity of promoters I.3, I.1 and I.7 was significantly higher in tumor tissues compared with non-malignant tissues. In 4 of 15 cases of non-small cell lung cancer, switching from CYP19 promoter I.4 to the alternative promoters II, I.1 or I.7 was observed. In 9 cases, there were significantly higher levels of aromatase mRNA in lung tumor tissues compared with adjacent non-malignant tissues. These findings suggest aberrant activation of alternative CYP19 promoters that may lead to upregulation of local aromatase expression in some cases of NSCLC. Further studies are needed to examine the impact of alternative CYP19 promoter usage on local estrogen levels and lung tumor growth.

## Introduction

Aromatase catalyzes the rate-limiting step in estrogen biosynthesis, the aromatization of androgens. A single gene (CYP19) encodes aromatase, and activation determines the presence or absence of aromatase enzyme activity in cells or tissues [1]. The entire aromatase gene spans approximately 123 kb and is transcribed from the telomere to the centromere [1-3]. The 30-kb 3'-end of the gene contains 9 exons (II-X) that encode the aromatase protein. The ATG translation initiation site is located 38 bp downstream of a common splice acceptor site in coding exon II. The 93-kb 5'-flanking region of the gene contains a number of tissue-specific promoters with unique 5'-untranslated first exons that are spliced onto a common splice junction such that each promoter-specific mRNA species encodes an identical aromatase protein [1].

The farthest upstream promoter is I.1, and its activity causes splicing of exon I.1 onto the common splice acceptor site, 93 kb downstream. The most proximal promoters, the gonad-specific promoter II and two other proximal promoters, I.3 (expressed in adipose tissue and breast cancer) and I.6 (expressed in bone) are located within the 1-kb region upstream of the common splice junction. The promoters specific for the brain (I.f) and skin (I.4) are localized at approximately 33 kb and 73 kb, respectively, upstream of the common splice junction [1, 4]. In adipose tissue or cultured adipose fibroblasts from breast, abdomen, buttocks and thighs, promoters I.4 (major) and I.3/II (minor) are used [4].

Estrogens contribute to differentiation and maturation in normal lung [5] and also stimulate growth and progression of non-small cell lung cancer (NSCLC) [6, 7]. As in breast, aromatase mediates the synthesis of local estrogen in lung tissues, which may affect lung tumor progression in estrogen receptor-expressing malignancies [8-10]. Aromatase inhibitors have recently been reported to repress lung tumor growth *in vitro* and in xenografts in nude mice [11].

The molecular basis for the CYP19 gene regulation in the lung remains poorly understood. In the present study, we demonstrate that CYP19 promoter I.4 is dominant in both lung tumor tissue and non-malignant tissues, though at a lower level than in non-malignant tissues, and that there is

aberrant activation of alternative CYP19 promoters and increased aromatase mRNA levels in some NSCLC tumor tissues.

## **Materials and Methods**

### **Patients**

We assessed tumor tissue and adjacent non-malignant tissue from 15 patients with NSCLC. The patient characteristics are listed in Table 1. The subjects without a smoking history were regarded as non-smokers, those who had a smoking history of one year or longer but did not smoke as ex-smokers, and those who smoked as current smokers. The Brinkman Index was calculated for the ex- and current smokers based on the number of cigarettes smoked each day and the number of smoking years. The purpose of the study was explained, and written informed consent was obtained from all study patients. The study protocol was approved by the ethics committees of University of Fukui Hospital and Northwestern University Feinberg School of Medicine. Tissue samples were collected at the time of surgery or autopsy at the University of Fukui Hospital. All samples were stabilized at 4°C overnight by RNA-later liquid (Applied Biosystems, Foster City, CA) immediately after surgery or autopsy, and then moved to -20°C until analyses. Tumor tissue and adjacent non-malignant tissue were in the same lobe and approximately 10 cm apart from each other.

### **Multiplex RT-PCR**

To study promoter usage in the CYP19 gene by multiplex RT-PCR, we designed 9 different amplicons from 303 to 373 bp (Fig. 1), as described previously [12]. This method has been validated in 2 different reports [12, 13]. The primers used in this study were: I.1 forward, 5'-ctg tgc tcg gga tct tcc-3', I.2 forward, 5'-ggc ttc ctg act ttc aac ag -3', I.3 forward, 5'-cct tgt ttt gac ttg taa cca-3', I.4 forward, 5'-gac caa ctg gag cct gac ag-3', I.6 forward, 5'-taa att gat tgt ctt gca cag g-3', I.7 forward, 5'-gaa gta aga ccg gag aaa ggg-3', I.8 forward, 5'- tca tat tgg gag gag ctt gg -3', PII forward, 5'-tcc ctt tga ttt cca cag gac tc-3', common reverse, 5'-ctc cat aca ccc ggt tgt ag-3'. The reverse primer was located at common exon III and labeled with 6-carboxyfluorescein [FAM] to quantitate promoter-specific mRNA species. The PCR reaction was set as follows: denaturation at

96°C for 5 min, then 45 cycles at 96°C for 30 sec, 58°C for 30 sec and 72°C for 30 sec. After PCR amplification, RT-PCR products were separated on an ABI3100 capillary sequencer and quantified by GeneScan software (Applied Biosystems).

### **Real-time RT-PCR**

mRNA was reverse-transcribed from total RNA using Superscript III (Invitrogen, Carlsbad, CA) and random hexamer primers. Real-time PCR was then performed to amplify the coding region of the CYP19 gene and GAPDH as a control, using TaqMan Gene Expression Assays (Applied Biosystems). PCR amplifications were performed in an ABI PRISM 7900 Sequence Detection System (Applied Biosystems) according to the manufacturer's instructions. cDNA (2 µl) was added to the PCR mixture in a final volume of 20 µl. Thermal conditions were 50 °C for 2 min, 95°C for 10 min and then 40 cycles of 95°C for 15 sec and 60°C for 1 min. PCR amplifications were performed in triplicate.

### **Statistical analysis**

All statistical analyses were conducted using the StatView statistical software. Statistical comparison of CYP19 gene promoter usage and expression levels in lung tumor and adjacent non-malignant tissues was done by Wilcoxon signed-ranks test or Student's t-test. P values of <0.05 were considered statistically significant.



## **Results**

### **CYP19 promoter usage in lung tumor and adjacent non-malignant tissues**

Non-malignant lung tissues from almost all cases employed promoter I.4, though two cases primarily used promoters I.3/II (Fig. 2). Although I.4 was the dominant promoter used in tumor tissues, I.4 usage was significantly lower in lung tumor tissues compared with adjacent non-malignant tissues. Tumor tissues also showed use of promoters I.3, I.1 and I.7 (Fig. 2). In tumor tissues from 4 of the 15 cases, promoter switching from I.4 to II, I.1 or I.7 was observed. These observations suggest aberrant activation of alternative CYP19 promoters in lung cancer.

### **Aromatase mRNA levels in lung tumor and adjacent non-malignant tissues**

Aromatase mRNA levels in 9 of 15 lung tumor tissues were significantly higher than those in adjacent non-malignant tissues (Fig. 3). A statistically significant difference in aromatase mRNA levels between lung tumor and corresponding non-malignant tissues was observed (Fig. 4).

## Discussion

The poor long-term survival rate in patients with NSCLC has driven the search for novel therapeutic targets through a better understanding of the disease pathology. The findings of a number of previous studies suggest that treatments targeted to estrogen signaling pathways may have anti-tumor efficacy in lung cancer [7, 11, 14-18]. Aromatase inhibitors have been used in therapeutic regimens for estrogen-dependent disorders such as breast cancer, endometriosis and uterine fibroids, but their application in lung cancer has not been considered. Our study adds to the growing body of evidence that aromatase inhibition may be a new therapeutic option for patients with lung malignancies.

Our results show that non-malignant lung tissue from NSCLC patients maintained low levels of aromatase expression, primarily via promoter I.4, which lies 73 kb upstream of the common coding region. Lung tumor tissue also primarily employed promoter I.4, though at a lower level than adjacent non-malignant tissue. The most distal promoter, I.1, was used only minimally in non-malignant lung tissue, but was used at much higher levels in lung tumor tissue. Promoters I.3 and I.7 were also upregulated in lung tumor tissue. Thus, total aromatase expression in lung tumor tissue was comprised of the sum of mRNA species arising from four promoters (I.4, I.1, I.3 and I.7), while normal lung tissue aromatase expression arose almost exclusively from promoter I.4 activation. Future studies will determine the impact of CYP19 promoter switching in lung cancer on aromatase activity and local production of estrogen.

Epithelial-stromal interactions enhance estrogen formation, desmoplastic reaction, and angiogenesis in a breast tumor [19, 20]. Breast cancer appears to take advantage of four promoters (II, I.3, I.7, and I.4) for aromatase expression [21]. The use of proximal promoters II/I.3 are strikingly up-regulated in adipose tissue adjacent to breast cancer and in breast cancer tissue per se. Aromatase is overexpressed in vascular endothelial cells of breast tumor tissue via promoter I.7. We observed that activity of promoters I.3, I.7 and I.4 was up-regulated in lung

tumor tissue. Complex tumor-stromal interactions may favor angiogenesis and increased local estrogen concentrations in lung tumors.

Alternative promoters of the CYP19 gene have been shown to be differentially regulated. Cyclic AMP (cAMP)-dependent transcription factors regulates proximal promoters PII/I.3 via two proximal cAMP response elements [22], whereas the glucocorticoid receptor (GR) induces promoter I.4 transcription via a GR binding element [23]. Interaction between the transcription factor GATA-2 and a specific GATA cis-regulatory element in promoter I.7 plays a critical role in its regulation [24]. These facts suggest that the activation of a particular CYP19 promoter may be specifically blocked, such that promoters found to be aberrantly activated in disease states can be targeted by therapeutics. In this case, a novel therapeutic strategy for estrogen-dependent NSCLC may involve targeting of the signaling pathways responsible for activation of promoters I.1, I.3 and I.7.

Though aromatase inhibitors are well tolerated, they can cause unwanted side effects related to systemic estrogen deprivation, such as bone loss. New therapeutic strategies that more effectively target aromatase expression and activity are needed. Our study provides new information on promoter usage in individual patients with NSCLC. In combination with information about estrogen receptor status, an understanding of CYP19 promoter usage in individual patients with lung cancer may lead to personalized approaches that more specifically suppress aromatase expression only in lung tumor tissues.

In the present study, we revealed that promoter I.4 was dominant in both lung tumor and non-malignant tissues, and that the alternative promoters I.3/II, I.1 and I.7 were aberrantly and heterogeneously activated in the lung tumor tissues from certain patients with NSCLC. Further study is essential to elucidating the *trans* and/or *cis* acting factors involved in ectopic activation of these promoters in lung cancer, as well as the impact of CYP19 promoter switching on local aromatase activity and estrogen levels, and lung tumor growth and progression.

**Conflict of interest:** The authors have nothing to disclose.

**Acknowledgement:** This work was supported by NIH (C67167), AVON Foundation, Lynn Sage Foundation, and Northwestern Memorial Foundation and Friends of Prentice (S.E.B.)

## References

- [1] Sebastian S, Bulun SE. A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. *J Clin Endocrinol Metab* 2001;86:4600-2.
- [2] Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. *J Steroid Biochem Mol Biol* 2003;86:219-24.
- [3] Kamat A, Mendelson CR. Identification of the regulatory regions of the human aromatase P450 (CYP19) gene involved in placenta-specific expression. *J Steroid Biochem Mol Biol* 2001;79:173-80.
- [4] Mahendroo MS, Mendelson CR, Simpson ER. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. *J Biol Chem* 1993;268:19463-70.
- [5] Patrone C, Cassel TN, Pettersson K, Piao YS, Cheng G, Ciana P, et al. Regulation of postnatal lung development and homeostasis by estrogen receptor beta. *Mol Cell Biol* 2003;23:8542-52.
- [6] Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Christie N, et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. *Cancer Res* 2002;62:2141-50.
- [7] Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. *Steroids* 2005;70:372-81.
- [8] Pezzi V, Mathis JM, Rainey WE, Carr BR. Profiling transcript levels for steroidogenic enzymes in fetal tissues. *J Steroid Biochem Mol Biol* 2003;87:181-9.
- [9] Brodie A, Long B, Lu Q. Aromatase expression in the human breast. *Breast Cancer Res Treat* 1998;49 Suppl 1:S85-91; discussion S109-19.
- [10] Oyama T, Kagawa N, Sugio K, Uramoto H, Hatano O, Harada N, et al. Expression of aromatase CYP19 and its relationship with parameters in NSCLC. *Front Biosci* 2009;14:2285-92.
- [11] Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, et al. Aromatase inhibitors in human lung cancer therapy. *Cancer Res* 2005;65:11287-91.
- [12] Demura M, Reierstad S, Innes JE, Bulun SE. Novel promoter I.8 and promoter usage in the CYP19 (Aromatase) gene. *Reprod Sci* 2008;15:1044-53.
- [13] Ishikawa H, Reierstad S, Demura M, Rademaker AW, Kasai T, Inoue M, et al. High aromatase expression in uterine leiomyoma tissues of African-American women. *J Clin Endocrinol Metab* 2009;94:1752-6.
- [14] Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. *J Natl Cancer Inst* 1994;86:869-70.
- [15] Mollerup S, Jorgensen K, Berge G, Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. *Lung Cancer* 2002;37:153-9.
- [16] Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, et al. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. *Clin Cancer Res* 2005;11:5084-9.

- [17] Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. *Cancer Res* 2005;65:1459-70.
- [18] Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. *Ann N Y Acad Sci* 2009;1155:194-205.
- [19] Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM, Bulun SE. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. *Cancer Res* 2001;61:2250-5.
- [20] Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. *Cancer Res* 2001;61:2328-34.
- [21] Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. *Pharmacol Rev* 2005;57:359-83.
- [22] Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. *Endocrinology* 1996;137:5739-42.
- [23] Shozu M, Sumitani H, Segawa T, Yang HJ, Murakami K, Kasai T, et al. Overexpression of aromatase P450 in leiomyoma tissue is driven primarily through promoter I.4 of the aromatase P450 gene (CYP19). *J Clin Endocrinol Metab* 2002;87:2540-8.
- [24] Sebastian S, Takayama K, Shozu M, Bulun SE. Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. *Mol Endocrinol* 2002;16:2243-54.

**Table**

**Table 1. Patient characteristics**

	Sex	Age	Histology	Smoking history	Brinkman index	Exposure to asbestos	Stage	Tissue collection
1	M	63	Well differentiated adenocarcinoma	Current smoker	400	No	1A	Surgical resection
2	M	64	Squamous cell carcinoma	Ex-smoker	2400	No	1A	Surgical resection
3	M	72	Squamous cell carcinoma	Ex-smoker	1500	No	3A	Surgical resection
4	F	76	Well differentiated adenocarcinoma	Never	0	No	3A	Surgical resection
5	M	75	Poorly differentiated adenocarcinoma	Current smoker	1100	No	1A	Surgical resection
6	M	59	Squamous cell carcinoma	Current smoker	600	Yes	1A	Surgical resection
7	F	58	Poorly differentiated adenocarcinoma	Never	0	No	3A	Surgical resection
8	F	38	Poorly differentiated adenocarcinoma	Never	0	No	3A	Surgical resection
9	M	70	Poorly differentiated adenocarcinoma	Ex-smoker	2000	No	1A	Surgical resection
10	F	66	Poorly differentiated adenocarcinoma	Never	0	No	1A	Surgical resection
11	M	62	Poorly differentiated adenocarcinoma	Current smoker	1680	No	4	Autopsy
12	F	77	Well differentiated adenocarcinoma	Never	0	No	2B	Surgical resection
13	M	82	Squamous cell carcinoma	Ex-smoker	1200	No	1A	Surgical resection
14	M	75	Well differentiated adenocarcinoma	Ex-smoker	680	No	1A	Surgical resection



15	F	80	Squamous cell carcinoma	Current smoker	800	No	1B	Surgical resection
----	---	----	-------------------------	----------------	-----	----	----	--------------------

M, male; F, female

## Figure legends

### Figure 1

Assessment of alternative CYP19 promoter usage. (A) Schematic of alternative tissue-specific exons I and promoters of the CYP19 gene. (B) RT-PCR products for multiplex PCR. 8 different amplicons from 303 to 373 bp were designed to detect tissue-specific first exons.

### Figure 2

Tissue-specific CYP19 gene promoter usage in lung tumor and adjacent non-malignant tissues by multiplex RT-PCR. Significant differences in promoter usage were observed for promoters I.3, I.1, I.4 and I.7, indicating aberrant activation of promoters I.3, I.1, and I.7 in lung cancer. The horizontal line represents the median, the box encompasses the 25<sup>th</sup> to 75<sup>th</sup> percentile and error bars encompass the 10<sup>th</sup> to 90<sup>th</sup> percentile. \* $p < 0.05$ , by Wilcoxon signed-ranks test.

### Figure 3

Comparison of aromatase mRNA levels in lung tumor and adjacent non-malignant tissues. In 9 out of 15 paired samples, there was significantly higher aromatase expression in lung tumor tissues compared with adjacent normal tissues. \* $p < 0.0001$ , \*\* $p < 0.001$ , \*\*\* $p < 0.05$ , † $p < 0.01$ , by two tailed Student's t-test.

### Figure 4

Boxplot summary of CYP19 mRNA levels in lung tumor and adjacent non-malignant tissues. There were significantly higher aromatase mRNA levels in lung tumor tissues compared with adjacent non-malignant tissues. The horizontal line represents the median, the box encompasses the 25<sup>th</sup> to 75<sup>th</sup> percentile and error bars encompass the 10<sup>th</sup> to 90<sup>th</sup> percentile. \* $p < 0.05$ , by Wilcoxon signed-ranks test.

Figure 1A




Figure 1B




Figure 2




Figure 3




Figure 4

